<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0DE6810-C22C-433E-9160-263AFCEF5D4D"><gtr:id>A0DE6810-C22C-433E-9160-263AFCEF5D4D</gtr:id><gtr:name>Ludger Ltd</gtr:name><gtr:address><gtr:line1>Culham Science Centre</gtr:line1><gtr:postCode>OX14 3EB</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Genetics and Molecular Medicine</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0DE6810-C22C-433E-9160-263AFCEF5D4D"><gtr:id>A0DE6810-C22C-433E-9160-263AFCEF5D4D</gtr:id><gtr:name>Ludger Ltd</gtr:name><gtr:address><gtr:line1>Culham Science Centre</gtr:line1><gtr:postCode>OX14 3EB</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/259A9C4C-8DF6-48F9-B626-B414032F4DC8"><gtr:id>259A9C4C-8DF6-48F9-B626-B414032F4DC8</gtr:id><gtr:firstName>Frank</gtr:firstName><gtr:surname>Nestle</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D488F9E2-71B9-460D-A435-0951340D01E7"><gtr:id>D488F9E2-71B9-460D-A435-0951340D01E7</gtr:id><gtr:firstName>Sophia</gtr:firstName><gtr:otherNames>N.</gtr:otherNames><gtr:surname>Karagiannis</gtr:surname><gtr:orcidId>0000-0002-4100-7810</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL023091%2F1"><gtr:id>7B8B4538-26B5-4B1A-89C7-6603177B242B</gtr:id><gtr:title>Preclinical efficacy of an antibody of the IgE class against a melanoma-associated antigen</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L023091/1</gtr:grantReference><gtr:abstractText>Cancer treatments which mobilise the patient's own immune system to fight cancerous cells (immunotherapy) are proving to be an exciting new approach in the fight against cancer. Antibodies are proteins that recognise alien entities in the body and trigger their destruction by immune cells. Antibodies recognising surface proteins (antigens) on cancer cells are now generated in the laboratory, designed to specifically seek out tumours displaying these surface antigens. To work, antibodies must also bind to immune cells, which in turn target those cancer cells. Antibodies come in five types, but only one, IgG, has been used in cancer therapy. Unfortunately, IgG binds relatively poorly to immune cells and works inefficiently in tissues, where tumours grow. Another antibody type, namely IgE, known as the key component of allergies, may be better suited to cancer therapy, because of its excellent binding to immune cells and ability to activate these cells in tissues. Our earlier work on designing IgE antibodies in relation to the therapy of ovarian cancer has already elicited encouraging results that engender optimism and we plan to test this antibody in patients soon.
We are now working to apply the same principles towards the treatment of the most lethal skin cancer, malignant melanoma. Melanoma cells are subject to immune scrutiny, that is they display on their surfaces antigens, the targets for an antibody. To investigate this, we produced CSPG4 IgE, an antibody specifically recognising melanoma cancer cells. When we tested this antibody in the laboratory, it was very effective in activating immune cells to destroy cancer. We now plan to complete these studies so that this therapy may benefit patients with malignant melanoma for whom few effective therapies are available.</gtr:abstractText><gtr:technicalSummary>The clinical landscape for the lethal skin cancer, melanoma, is transformed by novel agents including an antibody targeting T-cell regulatory pathways, which, despite moderate clinical responses and high toxicities, demonstrates promise for antibody therapies. Yet, there are presently no antibodies directly targeting melanoma cells. This strategy entails an antibody targeting melanoma antigens that is engineered with Fc regions of the IgE antibody class. Attributes of IgE such as natural tissue immune activatory functions and high affinity for cognate Fc receptors on frequently tumour-resident effector cells can translate into superior protection against solid tumours compared to conventionally-used IgGs. These advantages are demonstrated by efficacy and safety in three in vivo tumour models and remarkable progress through process development of our successful first IgE antibody targeting Folate Receptor alpha-expressing cancers, now approaching first-in-man clinical trials supported by the CRUK New Agents Committee. We engineered IgE and IgG1 antibodies recognising CSPG4, a cell surface tumour antigen over-expressed by 80% of melanomas; CSPG4 participates in melanoma pathogenesis and progression through activation of key signalling pathways. CSPG4 IgE demonstrated superior efficacy in targeting melanoma and direct and cell-mediated tumour-killing activities, suggesting a multifactorial mode of action. Background IP is owned by KCL through a PCT application filed in 2011. Here, we will evaluate efficacy and safety of this agent through functional assays on patient and healthy volunteer blood and in disease-relevant models, some of which will also serve to support future evaluations in the pre-clinical development and clinical study stages. Study design is based on expertise with our lead antibody, to directly progress CSPG4 IgE to process development and clinical trials.</gtr:technicalSummary><gtr:potentialImpactText>Substantial knowledge on Th2 immunity in cancer and IgE functions in the context of cancer therapy is presently being acquired in conjunction with our parallel on-going research and development activities with our lead agent. These activities are fully supported from funds independent to this application and will contribute added-value to our existing activities. Collectively, our research and development activities and knowledge acquired as part of this proposed study towards the clinical application of the concept for a second target and in a different set of clinical indications are of paramount importance towards making this approach widely applicable for cancer therapy. 
There are several options for the future progression of the programme, especially in relation to other cancer types known to express CSPG4. This would include expansion into larger indications such as breast cancer, including breast carcinomas termed &amp;quot;triple-negative.&amp;quot; This latter programme, as part of our newly funded Breakthrough Breast Cancer Unit at King's College London/Guy's Hospital (5-year Unit headed by Prof. Andrew Tutt; co-PIs: Karagiannis, Nestle, Ng) will commence with in vitro and in vivo models of breast cancer. Application as a therapy for breast cancer and specifically for triple-negative breast carcinomas is expected to report results in parallel with data acquired as part of this proposed study and will provide added value to this study. 
This study also stands to make a substantial impact in the wider field of immune and antibody therapeutics. Our research on Th2 immunity, IgE and cancer is receiving increasing attention from the academic, medical and biotechnology communities. We have been approached by three biotechnology companies (Novartis, Biotechnol, UCB) who have shown strong interest specifically in relation to IgE immunotherapy, for example toward a collaborative effort to develop IgE antibody fragments with multiple specificities including CSPG4
If successful this proposed study will: a) point to strategies by which Th2 immune responses could be harnessed to target tumours; b) provide a new therapeutic avenue to potentially benefit the majority of the 112,000 in the UK living with malignant melanoma; c) pave the way towards the development of a new class of therapeutic antibody agents with improved immune activatory functions which could be redirected against cancers of different origins. 
If unsuccessful, this study will be informative in informing the design of novel immune activatory strategies, especially those aimed at overcoming tumour-induced immune escape mechanisms and those aimed at re-educating inflammatory cells to attack rather than promote tumour growth.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>977991</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludger Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Defining and designing altered IgE glycoforms</gtr:description><gtr:id>CC2B65D1-88E8-42E1-BB47-3734EFC702D3</gtr:id><gtr:impact>Work has begun using high-performance glycoanalytics to establish a cost effective, flexible, operationally simple and potentially generic method for the glycoengineering of recombinant therapeutic glycoproteins.</gtr:impact><gtr:outcomeId>58c560fa6bb8e0.49934651-1</gtr:outcomeId><gtr:partnerContribution>Ludger Ltd provide high-performance glycoanalytics to establish a cost effective, flexible, operationally simple and potentially generic method for the glycoengineering of recombinant therapeutic glycoproteins.</gtr:partnerContribution><gtr:piContribution>Our laboratory is leading novel work to examine the role of glycans for IgE activity, and to exploit this knowledge for the development of altered IgE glycoforms. Bringing together expertise in IgE pharmacology (Karagiannis), chemical inhibitors of glycan biosynthesis (Wagner) and high-performance glycoanalytics (Ludger Ltd), we will provide proof-of-concept for a cost effective, flexible, operationally simple and potentially generic method for the glycoengineering of recombinant therapeutic glycoproteins.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>The South East London Cancer Consumer Panel for Research SELCRP</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9A9E8989-5A43-452F-AC53-8ADB47C39F51</gtr:id><gtr:impact>I serve as a panel member (researcher expert/representative) supporting the panel's work providing research and ethics feedback to researchers.</gtr:impact><gtr:outcomeId>56dd5832cff581.70264078</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.guysandstthomasbrc.nihr.ac.uk/PatientsPublic/Getinvolved/Haveyoursay/Cancer-research/Cancer-research.aspx</gtr:url><gtr:year>2013,2014,2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit by Breast Cancer Now and the Sarah Greene Tribute Fund members and supporters: King's College London/Guy's Hospital laboratory site visit, 31st Jan 2017</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>92178C20-7472-49F1-8056-B471C6C273FE</gtr:id><gtr:impact>Our team co-hosted an afternoon visit by Breast Cancer Now and the Sarah Greene Tribute Fund members and supporters: King's College London/Guy's Hospital laboratory site visit, 31st Jan 2017. This event included presentations, question and answer sessions and visits to our laboratory facilities with presentations from laboratory group members.</gtr:impact><gtr:outcomeId>58c559404fa9e1.89256432</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinical Trials Day held at Guy's Hospital in May 2015</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9429C1A9-07D3-4B06-AB52-FDD1773884D3</gtr:id><gtr:impact>Our team provided stall cover and a poster on IgE antibodies in oncology for the Clinical Trials Day at Guy's Hospital.</gtr:impact><gtr:outcomeId>56dd55a4f15a60.07101725</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Laboratory visit by patients and families from St John's Institute of Dermatology (skin cancer support group) on the 21st April 2016, St John's Institute of Dermatology, 9th floor, Guy's Tower Wing.</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A5DE538A-3C8B-444B-8403-4FE71AEE76BA</gtr:id><gtr:impact>The Karagiannis group hosted an afternoon meeting and visit to the laboratories by patients and families from St John's Institute of Dermatology (skin cancer support group) on the 21st April 2016, St John's Institute of Dermatology, 9th floor, Guy's Tower Wing. Co-hosts: Consultant Dermatologist, Consultant Medical Oncologist, Clinical Psychologist, Skin Cancer, St John's Institute of Dermatology.</gtr:impact><gtr:outcomeId>58c558a44d0363.04298562</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Guy's and St Thomas's NHS Trust Members' Health Seminar, Dermatology, 7th September 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2B631385-76DF-4F70-AF59-37D20D9CAAFF</gtr:id><gtr:impact>Invited to speak and engage with public at Guy's and St Thomas's NHS Trust Members' Health Seminar, Dermatology, 7th September 2016, Moles and Melanoma, Antibodies for cancer therapy; http://www.guysandstthomas.nhs.uk/news-and-events/past-events.aspx</gtr:impact><gtr:outcomeId>58c55b7d6a0103.52017893</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.guysandstthomas.nhs.uk/news-and-events/past-events.aspx</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radcliffe Department of Medicine Careers Day, St Anne's College, University of Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>937407CF-B3EB-4CF5-A601-13C59240BAA7</gtr:id><gtr:impact>Invited speaker at a Careers Day event, at St Anne's College, University of Oxford in April 2015</gtr:impact><gtr:outcomeId>56ddbaabb71f33.52219140</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.cardiov.ox.ac.uk/rdm-careers-day-2</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article in Nursing in Practice; Title: New tools to treat malignant melanoma.</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F10B268E-ED0D-48F2-A0BB-7E1DED8A6B54</gtr:id><gtr:impact>Lead author of article in nursing magazine. 
Karagiannis SN*, Lacy KE. New tools to treat malignant melanoma. Nursing In Practice. http://www.nursinginpractice.com/article/new-tools-treat-malignant-melanoma, 20 May, 2015</gtr:impact><gtr:outcomeId>56ddb8f4ae28d3.07861997</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.nursinginpractice.com/article/new-tools-treat-malignant-melanoma</gtr:url><gtr:year>2012,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker at Melanoma Discussion Group For Patients, Family &amp; Friends,  St John's Institute of Dermatology, Guy's and St Thomas' Hospitals NHS Trust</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>37A8C63B-BD3A-460B-8660-27C283DCE0BF</gtr:id><gtr:impact>Invited to this patient support group to discuss research on melanoma and design of antibodies including those of the IgE class.</gtr:impact><gtr:outcomeId>56dd5673130b94.19651428</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2013,2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>NIHR PhD studentship scheme</gtr:description><gtr:end>2021-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>FCCB21C7-3A63-47A1-BD08-D554CACC0945</gtr:id><gtr:outcomeId>58c54ac566e131.31790409</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EAACI Exchange Research Fellowship</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>European Academy of Allergy and Clinical Immunology (EAACI)</gtr:fundingOrg><gtr:fundingRef>For Ms Judit Fazekas from the Medical University of Vienna, Project title: Cloning And Characterization Of Anti-HER-2 Immunoglobulins Of Different Ig-Classes In Regard Of ADCC And ADCP</gtr:fundingRef><gtr:id>66B6222C-BD5B-45FB-894F-17826E141499</gtr:id><gtr:outcomeId>56dec964a93bd6.50898262</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>European Academy of Allergy and Clinical Immunology (EAACI) Task Force Status Award</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>European Academy of Allergy and Clinical Immunology (EAACI)</gtr:fundingOrg><gtr:fundingRef>AllergoOncology Task Force, Award for Task Force Activities part of the European Academy of Allergy and Clinical Immunology (EAACI)</gtr:fundingRef><gtr:id>D743DB1B-F27C-49CE-839C-7B60899226E1</gtr:id><gtr:outcomeId>58c55f6d907a02.20672076</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70794</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>E76EEF28-5F20-42C1-B2E8-4553DA14CA2B</gtr:id><gtr:outcomeId>58c5490b0b5209.86601959</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>258234</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Phase I study of MOv18, a first in class chimeric IgE antibody against folate receptor-a, in patients with advanced solid tumours: pre-clinical and clinical evaluations.</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>CDD73DC4-55D8-4A60-87CD-05C96E11676B</gtr:id><gtr:outcomeId>56be4b92af32e1.99089631</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2830</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Boehringer Ingelheim Fonds</gtr:department><gtr:description>Boehringer Ingelheim Fonds travel grant</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>Boehringer Ingelheim</gtr:fundingOrg><gtr:fundingRef>Ms Judit Fazekas, Medical University of Vienna, travelling fellowship to King's College London</gtr:fundingRef><gtr:id>BD3832E6-A351-4CBD-AA38-82A9BD973A15</gtr:id><gtr:outcomeId>58c54c111bcc58.76156143</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>This clinical study relates to MOv18 IgE, a chimeric anti-folate receptor alpha (FRa) monoclonal IgE antibody. Extensive pre-clinical research studies have led to this first-in-human (FIH), first-in-class, proof-of-concept trial of MOv18 IgE, in patients with advanced cancer to investigate the potential of the IgE class of antibodies in solid tumour indications.</gtr:description><gtr:id>2CBA6B0F-BA8D-4BDF-933A-379F5DCF66F5</gtr:id><gtr:impact>This trial is first time a therapeutic antibody of the IgE class has been administered to man. The data generated from the trial will
provide essential information to aid the development of this particular agent and other future IgE therapeutics, including IgE analogues of existing therapeutic IgG monoclonal antibodies, as well as new agents.</gtr:impact><gtr:outcomeId>56d593931c0851.59496643</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>MOv18 IgE: Phase I study of a first in class chimeric IgE antibody against folate receptor-a, in patients with advanced solid tumours</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>http://docplayer.net/31096743-London-cancer-alliance-clinical-trials-directory-phase-i-studies.html</gtr:ukcrnIsctnId><gtr:url>https://clinicaltrials.gov/ct2/show/NCT02546921</gtr:url><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D722BBC1-8112-402B-B49B-9CEF576B4C96</gtr:id><gtr:title>Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival.</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64b5af9189942a9600c7e57404549314"><gtr:id>64b5af9189942a9600c7e57404549314</gtr:id><gtr:otherNames>Wulaningsih W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn><gtr:outcomeId>585d7353a7cf09.07448009</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F6EDF7C-6B92-4C77-986F-2530F5645DA3</gtr:id><gtr:title>AllergoOncology: characterization of a monoclonal IgE antibody (SF-25 IgE) as a novel immunotherapy candidate for solid tumours</gtr:title><gtr:parentPublicationTitle>ALLERGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c13e2b4d5377824bff768275ec79803"><gtr:id>6c13e2b4d5377824bff768275ec79803</gtr:id><gtr:otherNames>Pellizzari G.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>5aa401eb8be3d3.87008215</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21F4AEC3-EE6C-4E75-A6CA-3DE1DBB0E199</gtr:id><gtr:title>AllergoOncology: IgE- and IgG-mediated immune mechanisms linking allergy with cancer and their translational implications.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97f8f42df40afcf8943e0fbac65d1b90"><gtr:id>97f8f42df40afcf8943e0fbac65d1b90</gtr:id><gtr:otherNames>Jensen-Jarolim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>5a35cfa1956a67.74909158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01CAF938-C648-490C-BF1E-C1D5F5853D2D</gtr:id><gtr:title>AllergoOncology: development of IgE antibodies for breast cancer immunotherapy</gtr:title><gtr:parentPublicationTitle>ALLERGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/306208882f5529de2690c15f04ed40ba"><gtr:id>306208882f5529de2690c15f04ed40ba</gtr:id><gtr:otherNames>Ilieva K.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>5aa401ebe34f34.73853350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E70939DD-1A87-4B74-BB43-FE943B769E6A</gtr:id><gtr:title>Abstract A089: The circulating memory B cell compartment of breast cancer patients is depleted in comparison with healthy volunteers</gtr:title><gtr:parentPublicationTitle>Cancer Immunology Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a16925a53618914435c1297f8685cc6"><gtr:id>1a16925a53618914435c1297f8685cc6</gtr:id><gtr:otherNames>Fittall M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2326-6066</gtr:issn><gtr:outcomeId>5aa401ed3c3852.54706632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>830DD3D7-9C86-4F73-9EBB-4073B9827A15</gtr:id><gtr:title>Recombinant plant-derived human IgE glycoproteomics.</gtr:title><gtr:parentPublicationTitle>Journal of proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04b9824353f56aab4518aae5acc0cbf2"><gtr:id>04b9824353f56aab4518aae5acc0cbf2</gtr:id><gtr:otherNames>Montero-Morales L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1874-3919</gtr:issn><gtr:outcomeId>5a2fd75b1a5617.15878608</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2503CADC-AC63-4D17-A60E-5A15B31C4561</gtr:id><gtr:title>Atopy and prostate cancer: Is there a link between circulating levels of IgE and PSA in humans?</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2e84d97f91605a250a9c2d39037e7ea"><gtr:id>b2e84d97f91605a250a9c2d39037e7ea</gtr:id><gtr:otherNames>Van Hemelrijck M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn><gtr:outcomeId>5aa32b0b214dc8.20480610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5339CC89-256D-496B-81CE-960CDA309441</gtr:id><gtr:title>Alternative activation of cutaneous B cells and IgG antibody subclass polarisation in melanoma</gtr:title><gtr:parentPublicationTitle>JOURNAL OF INVESTIGATIVE DERMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/727245205ee637d7c92fa017c7e01a81"><gtr:id>727245205ee637d7c92fa017c7e01a81</gtr:id><gtr:otherNames>Saul L.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>5aa401ec3fb308.77818846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54A5C926-46C4-487A-9F43-24FEE48ACA7F</gtr:id><gtr:title>Beta-glucan contamination of pharmaceutical products: How much should we accept?</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecee3102d6d0eea24f813f4ae1d3b415"><gtr:id>ecee3102d6d0eea24f813f4ae1d3b415</gtr:id><gtr:otherNames>Barton C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn><gtr:outcomeId>58c546bd4446e3.51689281</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DF2C791-292A-4949-9874-B00E0F0149D8</gtr:id><gtr:title>Targeting folate receptor alpha for breast cancer treatment</gtr:title><gtr:parentPublicationTitle>BREAST CANCER RESEARCH AND TREATMENT</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92a987e46f70878597bf933a04a0d291"><gtr:id>92a987e46f70878597bf933a04a0d291</gtr:id><gtr:otherNames>Cheung Anthony</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>5aa401ecb84694.22712133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09068EFF-4899-46A7-BCB0-3FED0283E57C</gtr:id><gtr:title>TGF-?-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination.</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ecf3873733a85d146c7f044153f1893"><gtr:id>2ecf3873733a85d146c7f044153f1893</gtr:id><gtr:otherNames>Cantelli G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn><gtr:outcomeId>56dd7bd79ba277.62572786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A125B03-32D0-4D37-B44C-19FB0D2F9AD7</gtr:id><gtr:title>BRAF inhibitors: resistance and the promise of combination treatments for melanoma.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7e58e18ab0a168c20e05d1a10288ff8"><gtr:id>e7e58e18ab0a168c20e05d1a10288ff8</gtr:id><gtr:otherNames>Griffin M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>5a34eb6c806265.45809245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D83CC72D-8245-41AB-AB34-2C537EBC7FED</gtr:id><gtr:title>AllergoOncology - the impact of allergy in oncology: EAACI position paper.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97f8f42df40afcf8943e0fbac65d1b90"><gtr:id>97f8f42df40afcf8943e0fbac65d1b90</gtr:id><gtr:otherNames>Jensen-Jarolim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>58c5474eb09c40.91397711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E0D628D-9B02-4FA1-8325-52599E3CECCB</gtr:id><gtr:title>Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97088b6667f0d3a3c5ac6a574fddd6a1"><gtr:id>97088b6667f0d3a3c5ac6a574fddd6a1</gtr:id><gtr:otherNames>Crescioli S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>5aa32b6e9fd953.25268633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BC79C39-B900-45BB-9925-E545E6D059E3</gtr:id><gtr:title>B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment.</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/301ac5ef7cae4868b174aef327f1bd2f"><gtr:id>301ac5ef7cae4868b174aef327f1bd2f</gtr:id><gtr:otherNames>Chiaruttini G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn><gtr:outcomeId>5a34eb7f73d997.32810015</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B981143-A330-4FBF-8AAF-F14DE6C40ECF</gtr:id><gtr:title>Revisiting the role of B cells in skin immune surveillance.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/555e07fab7901b6e4b9bfbcf200176b9"><gtr:id>555e07fab7901b6e4b9bfbcf200176b9</gtr:id><gtr:otherNames>Egbuniwe IU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn><gtr:outcomeId>5675def2426b2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E910115-4790-406E-8C56-665FC625F314</gtr:id><gtr:title>Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/246c72862f12b4547b1775bb22fe2c29"><gtr:id>246c72862f12b4547b1775bb22fe2c29</gtr:id><gtr:otherNames>Ilieva KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a2fd5c3751374.55308432</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82B12256-DAB3-4C0D-AFCB-122926512E8D</gtr:id><gtr:title>Therapeutic targets and new directions for antibodies developed for ovarian cancer.</gtr:title><gtr:parentPublicationTitle>mAbs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b9b8f51329782767b6c073691d2c327"><gtr:id>4b9b8f51329782767b6c073691d2c327</gtr:id><gtr:otherNames>Bax HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1942-0862</gtr:issn><gtr:outcomeId>58c5474e8a64f3.12399637</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B73A0433-6A61-4963-81E7-A367E35385E7</gtr:id><gtr:title>Patient-derived xenograft models of breast cancer with human immune components</gtr:title><gtr:parentPublicationTitle>BREAST CANCER RESEARCH AND TREATMENT</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83c0fd79a2bb7b4ea8fe89fc09d4744f"><gtr:id>83c0fd79a2bb7b4ea8fe89fc09d4744f</gtr:id><gtr:otherNames>Marlow Rebecca</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>5aa401ecdd55a0.62539060</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93ED47EA-2662-4962-B081-0E592EBA87DF</gtr:id><gtr:title>AllergoOncology: the canine IgE antibody 'can225IgE-?' triggers strong and specific effector-cell mediated cytotoxicity against EGFR plus tumor cells</gtr:title><gtr:parentPublicationTitle>ALLERGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bf348ceb753f9e74f0369e8395650db"><gtr:id>3bf348ceb753f9e74f0369e8395650db</gtr:id><gtr:otherNames>Fazekas J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>5aa32b0be20b19.45237862</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24BDB27F-E403-4953-B233-40285688D010</gtr:id><gtr:title>A human in vivo model of a cutaneous memory B cell immune response to skin antigen challenge</gtr:title><gtr:parentPublicationTitle>JOURNAL OF INVESTIGATIVE DERMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3a04578ae2970f3622bf9c9c11be5d1"><gtr:id>d3a04578ae2970f3622bf9c9c11be5d1</gtr:id><gtr:otherNames>Egbuniwe I. U.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>5aa401ec7631f8.98193111</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>530BED3E-149B-4919-90C4-489204A865F3</gtr:id><gtr:title>Ga-68 in vivo chelation with tris(hydroxypyridinone) ligands</gtr:title><gtr:parentPublicationTitle>EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e937d1e53c64b12398d7c61dc27e9533"><gtr:id>e937d1e53c64b12398d7c61dc27e9533</gtr:id><gtr:otherNames>Imberti C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1619-7070</gtr:issn><gtr:outcomeId>5aa401eb42bc05.65952693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>279DEF36-D2B6-4A15-90EE-F577F31074E9</gtr:id><gtr:title>Exploring folate receptor a immunotherapy of breast carcinomas: Human monocytic cell-mediated killing triggered by IgG1 and IgE antibodies</gtr:title><gtr:parentPublicationTitle>CANCER IMMUNOLOGY RESEARCH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d3c36f26369dbadffcd2b51d4f35e49"><gtr:id>5d3c36f26369dbadffcd2b51d4f35e49</gtr:id><gtr:otherNames>Fittall Matthew W.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2326-6066</gtr:issn><gtr:outcomeId>5aa401ed104358.72223860</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8F728BB-B503-4D32-8B02-BDCD2EFE71CE</gtr:id><gtr:title>Targeting folate receptor alpha for cancer treatment.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e79eb694a13631a2abaed50a822cc21"><gtr:id>7e79eb694a13631a2abaed50a822cc21</gtr:id><gtr:otherNames>Cheung A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58c5467593cc63.06172729</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE82CA15-4A7E-481A-8F53-BCE9B86C1F6A</gtr:id><gtr:title>Evaluating therapeutic IgE antibody toxicity using in vivo rat models and an ex vivo human basophil assay</gtr:title><gtr:parentPublicationTitle>ALLERGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a6b0722efaa8173967e6c1000f411b1"><gtr:id>3a6b0722efaa8173967e6c1000f411b1</gtr:id><gtr:otherNames>Bax H. J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>5aa32b0b7fe301.50557469</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C1351C8-6D6E-4EE2-B2D6-DB19DFA1EC24</gtr:id><gtr:title>IgG4 Characteristics and Functions in Cancer Immunity.</gtr:title><gtr:parentPublicationTitle>Current allergy and asthma reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97088b6667f0d3a3c5ac6a574fddd6a1"><gtr:id>97088b6667f0d3a3c5ac6a574fddd6a1</gtr:id><gtr:otherNames>Crescioli S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1529-7322</gtr:issn><gtr:outcomeId>56d5769967b7a2.68278036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2346CC3D-BB59-47D1-ABAA-5E3CFC92E787</gtr:id><gtr:title>Reprogramming macrophages against cancer cells with monoclonal antibodies</gtr:title><gtr:parentPublicationTitle>INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b707fb4879a417ff3085dae3ad470518"><gtr:id>b707fb4879a417ff3085dae3ad470518</gtr:id><gtr:otherNames>Karagiannis Sophia N.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1107-3756</gtr:issn><gtr:outcomeId>5aa32b0b5e2a40.54347822</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F417CE2-2068-45E3-8DBA-78BE7105EDCA</gtr:id><gtr:title>Allergooncology: folate receptor alpha as a therapeutic target in breast carcinomas using recombinant antibodies</gtr:title><gtr:parentPublicationTitle>ALLERGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/667f6c1e05eac839e9dbb577d1d0f8c2"><gtr:id>667f6c1e05eac839e9dbb577d1d0f8c2</gtr:id><gtr:otherNames>Cheung A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>5aa32b0b9d9048.14273364</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EF6F656-3B32-4F5E-B8A8-15BE21549523</gtr:id><gtr:title>Tumour-associated macrophage polarisation and re-education with immunotherapy.</gtr:title><gtr:parentPublicationTitle>Frontiers in bioscience (Elite edition)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f5cf125bb61b8a825e1364b81e3ebd6"><gtr:id>3f5cf125bb61b8a825e1364b81e3ebd6</gtr:id><gtr:otherNames>Josephs DH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1945-0494</gtr:issn><gtr:outcomeId>5675de3f31ff3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0F54C71-83B1-4864-8F0F-0C707EA590C0</gtr:id><gtr:title>Allergooncology: Functional evaluation of SF-25 IgE and IgG1 antibodies as novel candidates to activate human effector cells for cancer immunotherapy</gtr:title><gtr:parentPublicationTitle>ALLERGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c13e2b4d5377824bff768275ec79803"><gtr:id>6c13e2b4d5377824bff768275ec79803</gtr:id><gtr:otherNames>Pellizzari G.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>5aa32b0bc0b227.06871641</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>954439C1-2099-482A-B126-19D162151940</gtr:id><gtr:title>AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97f8f42df40afcf8943e0fbac65d1b90"><gtr:id>97f8f42df40afcf8943e0fbac65d1b90</gtr:id><gtr:otherNames>Jensen-Jarolim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>5a2fd5b8434f84.43237052</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7232182C-B699-44F6-9032-D287576F4AB0</gtr:id><gtr:title>Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a2dc4430704fbc2130d61551e683765"><gtr:id>4a2dc4430704fbc2130d61551e683765</gtr:id><gtr:otherNames>Hoffmann RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn><gtr:outcomeId>5a679418ddff48.35192441</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>420DDCBB-241D-4C5E-8475-359647A09A9C</gtr:id><gtr:title>An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like Tregs that Support a Tumorigenic Environment.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db1249502aac82c709192a06798e839c"><gtr:id>db1249502aac82c709192a06798e839c</gtr:id><gtr:otherNames>Halim L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a2fd5012e5345.61784684</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C91C10B3-4114-476C-94FF-3A5F2A587DA3</gtr:id><gtr:title>AllergoOncology: prognostic significance of elevated IgG4 levels in patients with cancer</gtr:title><gtr:parentPublicationTitle>ALLERGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d410eba82c16fb6df0c406a788abb60"><gtr:id>7d410eba82c16fb6df0c406a788abb60</gtr:id><gtr:otherNames>Karagiannis P.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>5aa401ec14d872.04530616</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2C99882-4C5D-45E0-BFF2-70BA66691711</gtr:id><gtr:title>Therapeutic IgE Antibodies: Harnessing a Macrophage-Mediated Immune Surveillance Mechanism against Cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c11f0fc7f828a365a5b00dfb947462a"><gtr:id>1c11f0fc7f828a365a5b00dfb947462a</gtr:id><gtr:otherNames>Karagiannis SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>5a34ebc24b2712.58572426</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6CE213F-E285-43EF-B6F6-F154588B068B</gtr:id><gtr:title>Abstract A009: IgG4: a new tool to predict the risk of disease progression in melanoma</gtr:title><gtr:parentPublicationTitle>Cancer Immunology Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1ca9da6894e26b6337b69fcd4be667c"><gtr:id>c1ca9da6894e26b6337b69fcd4be667c</gtr:id><gtr:otherNames>Karagiannis P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2326-6066</gtr:issn><gtr:outcomeId>5aa401ed639ff9.74783698</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A6CE162-B9A6-48FF-8815-D5114657952C</gtr:id><gtr:title>B cells and antibody responses in melanoma: Immune escape mechanisms and opportunities for translation</gtr:title><gtr:parentPublicationTitle>JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da57e98461a486c11eedadefbceba9cc"><gtr:id>da57e98461a486c11eedadefbceba9cc</gtr:id><gtr:otherNames>Karagiannis S. N.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0926-9959</gtr:issn><gtr:outcomeId>5aa32b0c174114.56826880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9823A59E-A3B3-493A-8AF2-001978F1232E</gtr:id><gtr:title>Development of downstream processing to minimize beta-glucan impurities in GMP-manufactured therapeutic antibodies.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a4eec9191390666fc60045d7ccd605d"><gtr:id>6a4eec9191390666fc60045d7ccd605d</gtr:id><gtr:otherNames>Vigor K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>58c546fd8c3073.50538621</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4A6946E-4800-4B26-A51E-9AC715550492</gtr:id><gtr:title>Anti-Folate Receptor-a IgE but not IgG Recruits Macrophages to Attack Tumors via TNFa/MCP-1 Signaling.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f5cf125bb61b8a825e1364b81e3ebd6"><gtr:id>3f5cf125bb61b8a825e1364b81e3ebd6</gtr:id><gtr:otherNames>Josephs DH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>58c5474e657480.82303986</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3FFE384-98F2-4549-8C75-8BD01CEF0025</gtr:id><gtr:title>IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f76e9f74d79333b9e957068eaf172892"><gtr:id>f76e9f74d79333b9e957068eaf172892</gtr:id><gtr:otherNames>Saul L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>585d735081a5e6.49146907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4359C14D-6464-4C08-9E50-D335AE440557</gtr:id><gtr:title>Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma.</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1ca9da6894e26b6337b69fcd4be667c"><gtr:id>c1ca9da6894e26b6337b69fcd4be667c</gtr:id><gtr:otherNames>Karagiannis P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn><gtr:outcomeId>56dd7d8fb945e7.73601226</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A04FA5E-47D1-4DFC-AE35-A0B058257382</gtr:id><gtr:title>Potential for monocyte recruitment by IgE immunotherapy for cancer in a rat model of tumour metastasis.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f5cf125bb61b8a825e1364b81e3ebd6"><gtr:id>3f5cf125bb61b8a825e1364b81e3ebd6</gtr:id><gtr:otherNames>Josephs DH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56dd7e74689940.61608289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72191D00-B406-45FC-9AAD-F4EACCB475E2</gtr:id><gtr:title>Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/246c72862f12b4547b1775bb22fe2c29"><gtr:id>246c72862f12b4547b1775bb22fe2c29</gtr:id><gtr:otherNames>Ilieva KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a678af0040c00.37761643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C846584E-8331-46F6-B0C6-03476FAAF15A</gtr:id><gtr:title>AllergoOncology: evidence for safety and efficacy of a tumour-specific IgE antibody therapeutic candidate for ovarian cancer immunotherapy in the presence of soluble circulating tumour-associated antigen</gtr:title><gtr:parentPublicationTitle>ALLERGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a6b0722efaa8173967e6c1000f411b1"><gtr:id>3a6b0722efaa8173967e6c1000f411b1</gtr:id><gtr:otherNames>Bax H. J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>5aa401ebb1f824.58308362</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L023091/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>